{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-26-005537","form_type":"8-K","ticker":"ETON","cik":"0001710340","company_name":"Eton Pharmaceuticals, Inc.","filed_at":"2026-02-25T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.966985+00:00","generated_at":"2026-05-16T00:21:57.882436+00:00","sec_items":["8.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Eton Pharmaceuticals receives FDA approval for DESMODA oral solution for central diabetes insipidus","bullets":["FDA approved DESMODA (desmopressin acetate) Oral Solution for central diabetes insipidus in all ages; first approved oral liquid formulation.","Commercial launch expected March 9; product available exclusively through Anovo specialty pharmacy.","Eton estimates >13,000 U.S. patients; potential peak sales of $30-$50M annually.","Patent protection through 2044; product leverages existing pediatric endocrinology rare disease sales team.","Key safety warning: risk of hyponatremia; fluid restriction recommended; contraindicated in moderate to severe renal impairment."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-26-005537","json":"https://secwatch.observer/filing/0001437749-26-005537.json","markdown":"https://secwatch.observer/filing/0001437749-26-005537.md","text":"https://secwatch.observer/filing/0001437749-26-005537.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1710340/000143774926005537/0001437749-26-005537-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1710340/000143774926005537/eton20260223_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T00:21:57.882436+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}